Revealing heavy losses in new SEC filing, video game therapeutic maker Akili details an uncertain financial future
Akili Interactive, makers of the first FDA-approved video game, rode its successes to a SPAC deal last month valuing the company at more than $1 billion. But in filing some of its first financial disclosures Monday, Akili revealed it has a tough road ahead to commercial profits.
In an S-4 filed with the SEC, the company said it made only about $377,000 in the first nine months of 2021 and incurred more than $41.6 million in expenses over the same time period. The steep operating losses came after Akili was more than $25 million in the red for all of 2020 and lost $21.5 million in 2019.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.